Successful North American tour for the PRI0

San Diego, Washington DC, New York ! What a fantastic holiday I hear you say….NOT.

Despite a day at the Zoo in San Diego (see very cute Panda ) it was all go in the US for the PRI. First stop San Diego after 20 hours of planes and airports with visits to several potential new members in La Jolla followed by the Global Engage – Microbiome R&D and Business Collaboration forum with over 400 attendees gathered together under the San Diego sunshine!

The sunshine played “second fiddle” however to lots of interesting presentations from the world of the Microbiome from the likes of Jack Gilbert, Rob Knight, Sarkis Masmanian and some really interesting commercial input from Ken Blount of Rebiotix and Ashton Harper of Protexin, amongst others!

A quick overnight flight across the US and the next morning I was in Washington DC, the nation’s capital, where it was, as you can see, raining; goodbye California sunshine! The Microbiome World Congress was run in conjunction with a Precision Medicine summit and was a more low-key affair than San Diego. However this gave me the opportunity to understand the FDA’s approach to interacting with LBP drug developers, as well as to meet with several potential new members of the PRI.

So far we have come back from the US with 4 new members for the PRI and hopefully several more in the coming weeks.

  • Matrisys Bioscience, founded in 2015, the company is developing rational microbiome therapies based on Dr. Richard L. Gallo’s basic and clinical research for the top 5 dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and skin infections, which have a huge impact on patients’ quality of life. More than 230 million patients suffer from these 5 skin diseases. We’d like to welcome Mark Wilson and the team to the PRI.
  • Microbiome Insights, situated in the heart of the University of British Columbia (UBC) campus, was born from both the Life Science Institute and the Personalized Medicine Initiative. The scientific backbone of the company is formed by UBC professors Dr. Brett Finlay and Dr. Bill Mohn, and CEO Malcolm Kendall. Understanding the microbiome is one of the fastest growing areas of science, and a critical part of investigating how microbes function in and interact with their environments. Our team of experts and testing methods combine to provide end-to-end service with comprehensive bioinformatics for clients interested in including microbiome analysis into their studies.
  • Quay Pharma – is a UK based CDMO with an exceptional depth of knowledge and experience that enables them to design novel and effective drug delivery systems built on a fundamental scientific and technical understanding of their clients’ requirements. They offer every client a bespoke approach matched precisely to their needs and circumstances.
  • Siolta Therapeutics, born out of the Lynch Laboratory at UCSF, they harness information from human microbiome studies to design next-generation microbial therapeutics that re-engineer the human microbiome to prevent or reduce inflammatory processes. Initial drug development is around asthma in children with many other therapeutics in the pipeline.

For those of you who don’t know us, the PRI is a European non-profit clearing the regulatory pathways forward for Microbiotic Medicinal Products, operating the only network in the Human Microbiome Supply Chain and promoting scientific exchange among our members. We also host a PharmabioticsGlobal conference in Paris every year in March!

 

The PRI is an interesting place for start-ups – CEO of Indigo Therapeutics, Pierre-Yves Mousset, MD0

Dr. Pierre-Yves Mousset, CEO of Indigo Therapeutics, discusses why joining the PRI is interesting for his start-up; regulatory affairs intelligence and making critical contacts in the industry of Live Biotherapeutic Products.

Pierre-Yves Mousset, MD; 20 years of experience in scientific medical consulting, former CEO of Draft Healthcare & Proteines communication agencies.

PRI grows by almost 60% in 2017 – Why not the US?0

The PRI membership has grown by approximately 60% in the last financial year. A mixture of pharmaceutical companies, traditional LBP developers and manufacturers, several start-ups (which is great because each one brings different science and innovation), sampling, DNA sequencing, CRO’s, CMOs, consultants, investment funds…the list goes on!

This growth in membership of course is a fair reflection of the buzz being felt in the Human Microbiome space and justifies our decision to focus on Microbiotic Medicinal Products (in particular LBPs). Another point of focus is of course that we are a European organisation looking to offer a clear regulatory pathway for our members when they take their products to market in Europe. We feel strongly that in order to do this we will also need to attract new members from North America and in the long term Asia.

November will be an interesting month; I’ll be traveling to the US and will be meeting with many people at the following conferences –

I’ll be happy to meet with people interested in the PRI at any of these events or even companies based in San Diego/La Jolla, DC or New York! Email or call on 0033661245717 and we can set up a meeting.

Richard Ellis, Business Development Manager, PRI

Interesting conference in Vienna and all the hard work still to be achieved to provoke the microbiotic medicine revolution!0

There’s a lot of movement in the world of Live Biotherapeutics, the Human Microbiome and taking medicines to market. Here at the PRI we realise that despite the enormous progress that has been made there remains a lot of work to be done in order to satisfy the pharmaceutical world as a whole.

I recently attended the Annual Microbiome Summit in Vienna, Austria and witnessed some excellent presentations from the likes of Benjamin Lelouvier of Vaiomer on Sequencing Blood Microbiota, Nick Monsul from Quorum Innovations on his work on the Skin Microbiome but the one that hit the most was by Marie Lindner of Novartis. Marie’s candid presentation was uncompromising, honest and backed by a strong understanding of both the pharmaceutical drug development process and Microbes; yes, I’m afraid Marie told it how it is! In the world of Big pharma the jury is still out on the Microbiome and although it hurts she backed it up with thoughtful and undiluted realism.

We’ve always been of the opinion that without Big Pharma on board then the Microbiome revolution will struggle to come about and it’s for this reason that we are driving awareness and promoting a collaborative effort towards the complex regulatory challenges that need to be overcome and combining our scientific knowledge and facilitating interaction within the human microbiome supply chain!

In order to achieve our goal as a catalyst in accelerating the above we are collaborating again with I²Media as scientific founders of Pharmabiotics Global 14-15 March 2018 and we will also be present at the following conferences and exhibitions throughout Europe and the US over the next 3-4 months:

To know more about the PRI and our concerns and objectives please do not hesitate to contact me Richard Ellis, Business Development Manager, on +33669002735 or richard@pharmabiotic.org.

Bugs Drugs & Beyond: Janssen Focused Microbiome-based Health Solutions0

Johson & Johnson’s Janssen Pharmaceutical Companies – the human microbiota and health

As soon as he is born, man becomes the habitat of a very rich microbial flora. The skin, the mucous membranes and the gastrointestinal contents become stocked with such a flora, but a very small number of these microorganisms have up to the present been recognised or described…For long it was thought that in healthy individuals all these micro-organisms were inoffensive and sometimes even useful.”

– Elie Metchnikoff, 1901, The Prolongation of Life

Unprecedented healthcare opportunity

The microbiome refers to the complex community of microbial organisms that live in, on and around us. In the early twentieth century, Metchnikoff proposed a scientific rationale for the beneficial effects of bacteria, hypothesizing their importance in health for the first time. Today, we understand that bacteria and the microbiome play a crucial role in both sickness and health, with the potential to maintain health, as well as prevent, intercept and cure disease.

Driving Innovation

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we’re interested in the human microbiome and the role ‘bugs’ play in impacting the health of consumers and patients, alike. We established the Janssen Human Microbiome Institute (JHMI) in 2015 to bring focus to microbiome expertise and innovations across Janssen and Johnson & Johnson. Headed by Dr. Dirk Gevers and headquartered in Cambridge, Massachusetts, the JHMI is a “one-stop shop” for microbiome innovators, offering experience and expertise to deliver microbiome-based health solutions to market.

The JHMI is working alongside researchers to deepen the understanding of host-microbe interactions, develop tools for standardized analytics, define regulatory pathways, and partner with the scientific community to advance translation of the science. Within the JHMI and across the J&J enterprise, our goal is to help innovators advance and bring about meaningful microbiome-based medicines, diagnostics, and solutions to individuals in order to improve and promote health and well-being.